Table 4.
The effects of targeted NSCLC therapies on QT interval (42).
Targeted Therapy | Odds of QT Prolongation | 99% CI |
---|---|---|
ALK inhibitors vs. EGFR/BRAF inhibitors combined | ROR 5.16 | 3.92 – 6.81 |
Crizotinib vs. other ALK inhibitors | ROR 1.91 | 1.22 – 3.00 |
Ceritinib vs. other targeted NSCLC therapies | ROR 3.43 | 2.02 – 5.81 |